An observational study in Acute Kidney Injury, Renal Dialysis and Renal Replacement Therapy, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Intermittent hemodialysis (IHD) is the first-line kidney replacement modality in 50% of severe acute kidney injury (AKI) cases in French intensive care units (ICUs). It clears uremic toxins and restores acid-base and fluid-sodium balance, but the osmotic imbalance it induces can cause or worsen hemodynamic and neurological failure. Dialysis dose is a major prognostic issue, yet the optimal target and the best tools to quantify it in AKI remain debated.
Kt/Vd, validated in chronic kidney disease, is largely biased in AKI because the urea distribution volume is altered by fluid overload, capillary hyperpermeability and impaired tissue perfusion. Alternatives include the urea reduction ratio (URR) and the solute removal index (SRI), simple measures that each require only one additional sample, but their relevance for guiding IHD strategy remains to be demonstrated. Kt alone is considered reliable in AKI, as urea clearance measured by ionic dialysance has been validated in the ICU, but neither Kt nor Kt indexed to body weight or body surface area has been evaluated in clinical practice.
Current recommendations set a minimum dose of three 4-hour sessions per week, with a blood flow > 200 mL/min and a dialysate flow > 500 mL/min. This target standardizes care and simplifies planning, but the lack of personalization and of session quality measurement may lead to an inadequate dose in some patients.
AIKIDDO is an observational study of 200 adult ICU patients with KDIGO stage 3 AKI treated with IHD. It aims to assess the agreement between dialysis dose measures (Kt/Vd, double-pool Kt/Vd, Kt, URR, SRI) obtained at each dialysis session. Patients are followed until Day 29 for death, dialysis dependence, renal recovery, neurological status, hemodynamic instability during sessions and duration of invasive mechanical ventilation.
1,691 studies on the registry are indexed under Acute Kidney Injury; 395 are open to participants now.
This study's planned enrollment of 200 is above the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients admitted to an intensive care unit who develop, during their stay, stage 3 acute kidney injury according to the Kidney Disease: Improving Global Outcomes (KDIGO) classification, requiring intermittent kidney replacement therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult ICU patients with KDIGO stage 3 AKI treated with IHD, either first-line or following continuous kidney replacement therapy. In these patients, the study assesses the agreement between different measures of dialysis dose (Kt/Vd, double-pool Kt/Vd, Kt, URR, SRI).
Other: Intermittent hemodialysis (no study-assigned intervention)
No intervention is assigned by the study. Patients receive IHD as part of their ICU care, and dialysis dose measures (Kt/Vd, double-pool Kt/Vd, Kt, URR, SRI) are obtained at each dialysis session.
Kt: volume of blood totally cleared of urea during the session (L)
Quantitative value of each dialysis dose parameter, measured at each dialysis session
Time frame: Up to 30 days
Kt/Vd: Kt divided by the patient's urea distribution volume (Vd, L)
Quantitative value of each dialysis dose parameter, measured at each dialysis session
Time frame: Up to 30 days
Double-pool Kt/Vd: Kt/Vd calculated with a double-pool urea kinetic model
Quantitative value of each dialysis dose parameter, measured at each dialysis session
Time frame: Up to 30 days
URR: urea reduction ratio, based on post-dialysis plasma urea
Quantitative value of each dialysis dose parameter, measured at each dialysis session
Time frame: Up to 30 days
SRI: solute removal index, based on urea in the effluent
Quantitative value of each dialysis dose parameter, measured at each dialysis session
Time frame: Up to 30 days
Death or dialysis dependence
Binary variable: death or dialysis dependence before Day 29 after inclusion.
Time frame: Up to day 29
Renal recovery
Defined by a glomerular filtration rate ≥ 60 mL/min/1.73 m2 (KDIGO).
Time frame: Up to day 29
CAM-ICU (Confusion Assessment Method for the ICU)
positive or negative for delirium
Time frame: At inclusion
CAM-ICU (Confusion Assessment Method for the ICU)
positive or negative for delirium
Time frame: At day 3
CAM-ICU (Confusion Assessment Method for the ICU)
positive or negative for delirium
Time frame: At day 6
CAM-ICU (Confusion Assessment Method for the ICU)
positive or negative for delirium
Time frame: At day 29
Glasgow Coma Scale
varying to 3 to 15, higher scores indicating better consciousness
Time frame: At inclusion
Glasgow Coma Scale
varying to 3 to 15, higher scores indicating better consciousness
Time frame: At day 3
Glasgow Coma Scale
varying to 3 to 15, higher scores indicating better consciousness
Time frame: At day 6
Glasgow Coma Scale
varying to 3 to 15, higher scores indicating better consciousness
Time frame: At day 29
RASS (Richmond Agitation-Sedation Scale)
-5 (unarousable) to +4 (combative), 0 meaning alert and calm.
Time frame: At inclusion
RASS (Richmond Agitation-Sedation Scale)
-5 (unarousable) to +4 (combative), 0 meaning alert and calm.
Time frame: At day 3
RASS (Richmond Agitation-Sedation Scale)
-5 (unarousable) to +4 (combative), 0 meaning alert and calm.
Time frame: At day 6
RASS (Richmond Agitation-Sedation Scale)
-5 (unarousable) to +4 (combative), 0 meaning alert and calm.
Time frame: At day 29
Hemodynamic instability
During IHD sessions Defined as vascular filling and/or initiation or increase of a vasopressor and/or discontinuation or reduction of the ultrafiltration rate.
Time frame: Up to day 29
Ratio of prescribed to delivered dialysis dose
At each dialysis session
Time frame: Up to day 29
Duration of invasive mechanical ventilation
During the ICU stay
Time frame: Up to day 29
Time to death or dialysis dependence
Time from diagnosis of AKI requiring IHD to death, or to Day 29 for patients alive at 30 days. Events are death before Day 29 and dialysis dependence at Day 29.
Time frame: Up to day 29
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →